Quality of evidence: C
Liver Impairment in COVID-19 Patients: A Retrospective Analysis of 115 Cases From a Single Center in Wuhan City, China
Authors: Zhang Y et al
Journal: Liver International
Objectives: Analyze the clinical significance of liver disturbances during COVID-19 and its relationship to disease progression
Strength of evidence: Low (Exclusions, low number of critical cases, correction for multiple comparisons missing, controls limited)
Methods/publication type:
A retrospective monocentric case-control study carried out in a hospital in Wuhan between 18/01/2020 and 22/02/2020.
115 patients hospitalized in 3 infectious disease departments receiving only COVID-19 patients
Controls: 114 patients hospitalized in pulmonology or critical care for community-acquired pneumonia over the same period.
Classification : severe case (FR> 30cycles / min or SpO2 <93% or PaO2 / FiO2 = <300mmHg) else mild case. No critical cases.
Initial biological examinations: NFS, coagulation assessment, routine biochemistry, hepatic assessment, then adapted to individual development.
Postmortem histopathological: hepatic needle biopsy within 1 hour of death examined by 2 pathologists.
Highlights :
The liver does not appear to be a major target for SARS-CoV-2
This could be explained by the low expression of ACE 2 in the liver
Few liver-associated anomalies reported
Comments